rinvatercept Updated Aug 27
Watch for the Phase 2 DMD initial data readout for rinvatercept expected in H1 2027, and any regulatory engagement updates for the ALS program in H2 2026. The stock trades at ~$11.23 with analyst mean price target of ~$19.83 (69% upside), but the stock is 18.8% below its 200-day SMA, reflecting the pre-revenue, binary-risk profile typical of clinical-stage biotechs.
- Phase 1 data in healthy volunteers showed target engagement, favorable changes in muscle and bone mass, and a good safety profile, supporting advancement into two Phase 2 trials (DMD and ALS).
- Keros has a strong balance sheet with $257.6M in cash providing runway into H1 2028, plus a $1.3B+ global licensing deal with Takeda for its other asset elritercept, which provides validation and potential milestone income.
- Analyst consensus is bullish: 9 Buy/Strong Buy vs 0 Sell, with a mean price target of ~$19.83, roughly 69% above the current ~$11.23 price.
- Rinvatercept is still in early-stage development, Phase 1 only completed in healthy volunteers, with no efficacy data in patients yet. Phase 2 DMD data won't read out until H1 2027, leaving a long period with no near-term binary catalysts.
- DMD and ALS are both notoriously difficult indications with high clinical trial failure rates. Multiple prior muscle-building approaches have failed in these diseases.
- The stock trades 18.8% below its 200-day SMA ($13.84) and has a 52-week range of $9.69-$22.55, reflecting significant volatility and the binary-risk nature of clinical-stage biotech.